$CTXR News

Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026

Citius Pharmaceuticals to Participate in October 2026 Investor Conferences

Citius Pharmaceuticals to Participate in September 2026 Investor Conferences

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Citius Pharma Q3 EPS $(0.34) Beats $(0.36) Estimate, Sales $1.494M Miss $5.467M Estimate

Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting

Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts?

HC Wainwright & Co. Assumes Citius Pharmaceuticals at Buy, Announces Price Target of $4

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

Citius Oncology Ships First International Order of LYMPHIR™ to Europe

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules

Citius Pharmaceuticals Secures $5M Through Equity Offering

Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules

Citius Pharmaceuticals shares are trading lower after the company announced a $5 million registered direct offering.

Citius Pharmaceuticals shares are trading lower after the company announced a $5 million registered direct offering.

UPDATE: Reported Earlier, Citius Pharma Prices $5M Offering Of 5,076,143 Shares At A Price Of $0.985/Share

We Might See A Profit From Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Soon

Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development

Citius Pharmaceuticals shares are trading higher after the company provided a commercial update on the U.S. launch of LYMPHIR for the treatment of cutaneous T-cell lymphoma.